3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN) (PHN)

A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Tolerability of 3VM1001 Cream for the Treatment of Pain Associated With Post-Herpetic Neuralgia: A Proof of Concept Study

Post-herpetic neuralgia (PHN) is pain following acute herpes zoster; defined as pain lasting longer than 3 months. Current first line management consists of tricyclic anti-depressants and anti-convulsants such as gabapentin and pregabalin. There is an unmet medical need for treatments got topical therapies that demonstrate efficacy without serious side effects.

Study Overview

• Status: Completed
• Conditions: Treatment of PHN
• Intervention / Treatment: Drug: 3VM1001; Other: Placebo

Detailed Description

Post-herpetic neuralgia (PHN) is defined as pain following acute herpes zoster (AHZ) lasting >3 months. PHN develops in about 10% of patients following an episode of AHZ. 95% of adults ate seropositive for varicella zoster virus antibodies, and are, therefore, at risk for AHZ and PHN. Wider use of AHZ vaccine approved in 2006 may reduce the incidence of PHN. Nevertheless, PHN may be severe and frequently interferes with daily activities and with sleep.

First line management of PHN pain currently is tricyclic anti-depressants and anti-convulsants such as gabapentin and pregabalin, and use of a 5% lidocaine patch. second line therapies include opioid analgesia and topical capsaicin: combinations of topical and systemic therapies may be used as well. These therapies have common side effects of dry mouth, constipation, sedation, urinary retention, nausea, somnolence, dizziness, weight gain and peripheral edema.

there is an unmet medial need for topical therapies that demonstrate efficacy without the significant side effects o the therapies mentioned above. 3VM cream, a low concentration of copper in a cream vehicle may b such a therapy.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60602
      • Medex Healthcare Research, Inc.
  • New York
    • New York, New York, United States, 10036
      • Medex Healthcare Reasearch, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 78 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of PHN for >3 months;
• Persistent pain for more than 6 months from appearance of herpes zoster rash that is not located above the scalp hairline, or in immediate proximity to mucous membranes (given the low toxicity of copper, PHN affecting the face and neck will be included, but subjects will be trained on avoidance of contact with the eyes or mouth);
• Age 18 years or older;
• Males or females of non-childbearing potential (i.e., 12 months or more of spontaneous amenorrhea, bilateral oophorectomy at least 6 months prior to randomization, hysterectomy with bilateral oophorectomy at least 6 months prior to randomization, or for females over 50 years of age, hysterectomy without bilateral oophorectomy at least 6 months prior to randomization); female subjects of childbearing potential must agree to use contraception (abstinence, birth control pills, rings or patches, diaphragm and spermicide, intrauterine device, condom and vaginal spermicide, surgical sterilization, vasectomy, progestin implant or injection); female partners of childbearing potential of male subjects must agree to use contraception as defined above;
• Persistent neuropathic pain that involves at least 1 dermatome and covering no more than 400 cm2 (the target area);
• Pain intensity in the target area of > 40mm on a 100mm VAS at screening;
• Intact skin over the target area to be treated;
• Subject agrees to take only the protocol-defined rescue medication as prescribed;
• All concurrent medications taken for any reason except for the treatment of PHN must be stable (dose, frequency) for 14 days;
• Ability to follow protocol with reference to cognitive and situational factors (eg. stable housing, ability to attend visits);
• Ability to read and write English;
• Ability to apply cream without assistance;
• Able to provide written informed consent.

Exclusion Criteria:

• Subject with systemic disease that would put him/her at an additional risk or limit his/her ability to participate in the study in the opinion of the investigator;
• Subject with known history of human immunodeficiency virus, hepatitis C, or hepatitis B;
• Malignancy other than basal cell carcinoma and carcinoma in situ within the past 2 years;
• Subject who has an active history of alcohol or drug abuse;
• Wilson's disease or other known disorder of copper metabolism;
• Known hypersensitivity or allergy to any component of the product, or to acetaminophen
• Pregnant and breastfeeding women.
• Subject with active herpes zoster lesions;
• Subject with open skin lesions or skin infections in the target area, or conditions over the target area such as eczema or psoriasis;
• Mild pain in the target area, characterized by VAS score of < 40 mm
• Pain in any other part of the body that could interfere with the patient's assessment of pain in the target area
• Subject who has taken concomitant medications for the treatment of PHN (except acetaminophen or gabapentin) in the last four weeks. If taking gabapentin the dose must have been stable for at least four weeks;
• Treatment with local anesthetic or steroids (including lidocaine patch, transcutaneous electrical nerve stimulation, etc.) in the last 2 weeks or nerve blocks within the last 30 days;
• Subject who has used capsaicin preparations on a regular basis in the 90 days prior to screening and at all in the past two weeks;

• Use of prohibited concomitant medications/therapies;

  1. Devices or therapeutic treatments for pain apart from acetaminophen as a rescue medication
  2. Systemic corticosteroids
  3. Other Investigational Drugs
  4. Chemotherapeutic drugs
  5. Immunotherapy
  6. Topical products applied to the target skin area
• Subject with history of serious mental illness or psychiatric illness such as dementia, depression, or schizophrenia, that will limit his/her ability to comply with study procedures;
• Subject who is unable to apply, or have a care giver apply, study ointment to the area of most painful skin segments, three times daily, once within 2 hours of waking, once mid-afternoon, and once prior to bedtime;
• Subject who has participated in any other investigational study within 60 days prior to screening;
• Subject who is employed by the Sponsor, study staff, and their families; or
• Subject who has any condition that would make him/her, in the opinion of the investigator or Sponsor, unsuitable for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 3VM1001 cream; Patients will be randomized to self treat with 2 g of VM1001 cream times daily for ten days, have a five day wash out period and then 10 days of self treatment with the comparator.	Drug: 3VM1001; Self treatment 3 times daily for 10 days
Placebo Comparator: Placebo; Patients will be randomized to self treat with either active product or placebo comparator thrice daily for 10 days followed by a 5 day wash out period then 10 days of experimental treatment thrice daily for 20 days.	Other: Placebo; Cream without investigational drug. Self treatment 3 times daily for 10 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The time averaged mean in a standard 100 mm visual analog scale (VAS).	The time averaged mean of all patient pain scores over each study period; trend over time for each treatment sill be assessed by day of therapy to evaluate any increase or decrease in effect for each study treatment.	25 days total

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events, serious adverse events, and study discontinuation	Collection of adverse events and the number of subjects discontinuing he study	25 days total
Patient Global Expression of change Scale (PGIC) from baseline (day 0) to the end of each study period.	This measure is a single-item rating by participants of their improvement with treatment on a 7-point sale that ranges from "very much improved" to very much worse" with "no change "the mid-midpoint".	25 days total
Change in Patient Global Assessment of Treatment Satisfaction from baseline to the end of each study phase.	Patient Global Assessment of Treatment Satisfaction from baseline to the end of each study phase. Patients will rate their overall satisfaction with study treatment using a 5-point categorical scale.	25 days total
Use of Rescue medication	recording of the use of rescue mediation at each phase of the study.	25 days total

Collaborators and Investigators

• Sponsor: CDA Research Group, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 6, 2017
• Primary Completion (Actual): March 30, 2018
• Study Completion (Actual): May 4, 2018

Study Registration Dates

• First Submitted: January 30, 2018
• First Submitted That Met QC Criteria: January 30, 2018
• First Posted (Actual): February 5, 2018

Study Record Updates

• Last Update Posted (Actual): July 10, 2018
• Last Update Submitted That Met QC Criteria: July 9, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Keywords: PHN, acute, herpes zoster
• Additional Relevant MeSH Terms: Nervous System Diseases; Pain; Neurologic Manifestations; Neuromuscular Diseases; Peripheral Nervous System Diseases; Neuralgia; Neuralgia, Postherpetic
• Other Study ID Numbers: 3VM0416

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No